Repression of human telomerase reverse transcriptase using artificial zinc finger transcription factors by 諛뺢킅洹�
2010;8:246-253. Published OnlineFirst February 9, 2010.Mol Cancer Res 
  
Joon Hyung Sohn, Byung-Il Yeh, Jong-Whan Choi, et al. 
  
Using Artificial Zinc Finger Transcription Factors
Repression of Human Telomerase Reverse Transcriptase
  
Updated version
  
 10.1158/1541-7786.MCR-09-0141doi:
Access the most recent version of this article at:
  
  
  
  
  
Cited Articles
  
 http://mcr.aacrjournals.org/content/8/2/246.full.html#ref-list-1
This article cites by 40 articles, 22 of which you can access for free at:
  
Citing articles
  
 http://mcr.aacrjournals.org/content/8/2/246.full.html#related-urls
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
on January 6, 2014. © 2010 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 
246
Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 Signaling and Regulation Molecular
CancerResearch
Repression of Human Telomerase Reverse Transcriptase
Using Artificial Zinc Finger Transcription FactorsJoon Hyung Sohn1,4, Byung-Il Yeh1,2,3, Jong-Whan Choi1,2, Joonho Yoon1, Jun Namkung1,
Kwang-Kyun Park4, and Hyun-Won Kim1,2AbstractAuthors' A
Medical Sc
Medicine,
Dental Scie
Yonsei Uni
Correspon
Yonsei Uni
lic of Kore
kimhwbio@
doi: 10.115
©2010 Am
Mol Canc
DownTelomerase activation is a key step in the development of human cancers. Expression of the catalytic sub-
unit, human telomerase reverse transcriptase (hTERT), represents the limiting factor for telomerase activity. In
this study, we have used artificial zinc finger protein (ZFP) transcription factors (TF) to repress the expression
of hTERT in human cancer cell lines at the transcriptional level. We have constructed four-fingered ZFPs
derived from the human genome which binds 12-bp recognition sequences within the promoter of the hTERT
gene and fused them with a KRAB repressor domain to create a potent transcriptional repressor. Luciferase
activity was decreased by >80% in all of the transcriptional repressors with luciferase reporter assay. When they
were transfected into the telomerase-positive HEK293 cell line, a decrease of mRNA level and telomerase
activity together with shortening of telomere length was observed. Actual growth of HEK293 cells was also
inhibited by transfection of artificial ZFP-TFs. The repression was maintained for 100 days of culture. The
repression of telomerase expression by artificial ZFP-TFs targeting the promoter region of the hTERT presents
a new promising strategy for inhibiting the growth of human cancer cells. Mol Cancer Res; 8(2); 246–53.
©2010 AACR.Introduction
A key property of malignant tumors is their immortality
or limitless replicative potential (1). It is believed that the
maintenance of telomeres is essential for the immortality of
cancer cells. Telomeres are maintained by a specialized re-
verse transcriptase, the ribonucleoprotein telomerase,
which is composed of a ubiquitously expressed RNA sub-
unit, human telomerase RNA component (hTERC; ref. 2),
and a protein catalytic subunit, human telomerase reverse
transcriptase (hTERT), the expression of which is highly
regulated (3, 4). The expression of hTERT represents the
limiting factor for telomerase activity. Therefore, the regu-
lation of hTERT at the transcriptional level could be an
effective method for cancer regulation.
Promoter characterizations of the hTERT gene have
been previously described (5-7). It has been suggested that
the hTERT core promoter, encompassing the proximal
283 bp region upstream of the initiation ATG codon, is
essential for transcriptional activation (Fig. 1A; ref. 8). Affiliations: 1Department of Biochemistry, 2Institute of Basic
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on January 6, 2014mcr.aacrjournals.org loaded from large number of transcription factors act on the promoter
of hTERT such as SP1 (6), c-MYC (9), the estrogen recep-
tor (10), E2F-1 (11), WT-1 (12), and MZF-2 (13). These
have been reviewed in recent investigations (14, 15).
The Cys2-His2 class of zinc finger protein (ZFP) is the
most common DNA-binding motif in the human genome
and provides an ideal scaffold for designing artificial tran-
scription factors (TF) with novel DNA sequence specifici-
ties. Due to their modular nature, zinc fingers could be
used like molecular building blocks to create multi-finger
domains recognizing extended DNA sequences (16).
Various artificially engineered ZFPs with DNA-binding
specificities were created by using phage display (17, 18).
These ZFPs could be used as modular building blocks in
the construction of sequence-specific DNA-binding pro-
teins. Fusion of these ZFPs with transcriptional repression
domains or activation domains could generate potent tran-
scriptional repressors or transcriptional activators control-
ling endogenous human genes as well as plant and viral
genes (19-24).
ZFPs could also be isolated by screening, in yeast, plas-
mid libraries that encode zinc fingers derived from human
genomes (25). Unlike ZFPs using phage display in which
mutations were incorporated at key positions in a given zinc
finger framework, ZFPs with sequences in the human ge-
nome could be used intact as wild-type, and were revealed
to be more natural and efficient for regulating human en-
dogenous gene expression than those selected in vitro using
phage display.
Telomerases are activated in a variety of tumors, and
only few tumors maintain telomeres by an alternative
mechanism which relies on recombination (26-28). In. © 2010 American Association for Cancer Research. 
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Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 contrast to normal somatic cells, telomerase is highly re-
activated in cancer cells. Thus, telomerase could be an
important target in developing new anticancer agents.
Many recent strategies have been targeting telomerase in-
hibition (15, 29-31).
In this study, we have artificially constructed four-fin-
gered ZFPs using the domains derived from the human ge-
nome, which bind 12 bp recognition sequences within the
core promoter of the endogenous hTERT gene (Fig. 1A).
We have created a potent transcriptional repressor domain
by fusing these ZFPs with a KRAB repressor domain
(Fig. 1B). Our results show that the artificial ZFP-TFs
technology could provide a new efficient method of
hTERT inhibition.Materials and Methods
Plasmid Construction
The cloning of ZFP-TFs has been previously described
(32, 33). The amino acid sequences of six ZFPs are: NH3
+-
PGEKPYKCGQCGKFYSQVSHLTRHQKIHTGE-
KPYKCPDCGKSFSQSSSLIRHQRTHTGEKPYK-
CMECGKAFNRRSHLTRHQRIHTGEKPYECEKC-
GKAFNQSSNLTRHKKSHTGEK-CO2
− [F-197R],NH3
+-
PGEKPYVCDVEGCTWKFARSDELNRHKK-
RHTGEKPYKCMECGKAFNRRSHLTRHQRIHT-
GEKPYKCKQCGKAFGCPSNLRRHGRTH -
TGEKPFQCKTCQRKFSRSDHLKTHTRTHTGEK-
CO2
− [F-153R], NH3
+-PGEKPYKCMECGKAFNRRS‐
HLTRHQRIHTGEKPYECNYCGKTFSVSSTLIRHQ-
RIHTGEKPYKCMECGKAFNRRSHLTRHQRIHT-
GEKPYKCGQCGKFYSQVSHLTRHQKIHTGEK-CO2
−
[F-122R],NH3
+-PGEKPFQCKTCQRKFSRSDHLKTH‐
TRTHTGEKPYKCMECGKA‐FNRRSHLTRHQRIHT-
GEKPYECNYCGKTFSVSSTLIRHQRIHTGEKPYKC-
MECGKAFNRRSHLTRHQRIHTGEK-CO2
− [F-105R],
NH3
+-PGEKPYKCMECG‐KAFNRRSHLTRHQRIHT-
GEKPYICRKCGRGFSRKSNLIRHQRTHTGEKPYKC-
MECGKAFNRRSHLTRHQRIHTGEKPYECEKCG-
KAFNQSSNLTRHKKSHTGEK-CO2
− [F-97R], NH3
+-
PGEKPYKCMECGKAFNRRSHLTRHQRIHTGEK-
PYTCSDCGKAFRDKSCLNRHRRTHTGEKPYVCD-
VEGCTWKFARSDELNRHKKRHTGEKPYKCMECG-
KAFNRRSHLTRHQRIHTGEK-CO2
− [F-5R]. Each
plasmid encoded the following fusion protein: hemaggluti-
nin tag-nuclear localization signal-ZFP-KRAB (Fig. 1B).
The KRAB repression domain used in these studies
contained 63 amino acids. They constitute the minimal seg-
ment which retains transcriptional repressor activity (32).
DNA segments that encode ZFPs were isolated by diges-
tion with EcoRI and NotI, and were inserted into pGEX-
4T2 (Amersham Pharmacia) for protein expression. These
constructs encoded ZFP–glutathione-S-transferase fusion
protein (Fig. 1C). The DNA fragment of the hTERT core
promoter, which is located 334 bp upstream of the ATG
initiation codon, was inserted into the KpnI and NcoI re-
striction site of pGL3-basic (Promega) promoterless andwww.aacrjournals.org
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serted DNA was amplified by nested PCR using GC-rich
PCR system (Roche) from HeLa Genomic DNA. The
primer sequences used for the first PCR were 5′-CAA
TGC GTC CTC GGG TTC GTC C-3′ (forward) and
5′-TCT CCG CAT GTC GCT GGT TCC C-3′ (reverse),
and for the second PCR were 5′-GGG GTA CCC CGG
AGC AGC TGC GCT GT-3′ (forward) and 5′-CAT
GCC ATG GCG CGG GGG TGG CCG-3′ (reverse).
The construct was named pGL3-hTERT. Each construct
was purified by Miniprep Kits (Qiagen) and confirmed
by sequencing (Genotech).
Cell Culture and Transfection of HEK293 Cells
HEK293 cells (American Type Culture Collection) were
maintained in DMEM supplemented with 100 units/mL
of penicillin, 100 mg/mL of streptomycin, and 10% fetal
bovine serum (all from Life Technologies) at 37°C in a 5%
CO2 humidified incubator. For transient transfections,
HEK293 cells (2 × 104 cells/well) were precultured for
24 h in 96-well culture plates (Becton Dickinson) that
contained 100 μL of the medium described above without
antibiotics. For some experiments, 105 cells per well were
cultivated in 24-well culture plates. Unless otherwise indi-
cated, the HEK293 cells were transfected with a nucleic
acid mixture at a total amount of 320 ng (for 96-well cul-
ture plates) or 1 μg (for 24-well culture plates). The nu-
cleic acid mixtures contain effector plasmids encoding
ZFPs (Fig. 1B), reporter plasmids encoding firefly lucifer-
ase (Fig. 2A), and internal control Renilla luciferase (pRL-
SV40; Promega). Transfection was done with the
LipofectAMINE 2000 reagent (Invitrogen) according to
the instructions of the manufacturer.
Electrophoretic Mobility Shift Assay
ZFPs in pGEX-4T2 were then expressed in Escherichia
coli strain BL21 (DE3) as fusion proteins linked to gluta-
thione-S-transferase. The fusion proteins were purified us-
ing glutathione affinity chromatography (Amersham
Pharmacia) and the connection between the glutathione-
S-transferase moiety and the ZFPs was digested with
thrombin. Probe DNAs were synthesized, annealed, and
labeled with 32P using T4 polynucleotide kinase. Next,
electrophoretic mobility shift assays were carried out as de-
scribed previously (25, 32).
Luciferase Assay
After incubation at 37°C for 48 h after transfection,
cultured cells were washed twice with PBS and mixed
with passive lysis buffer (30 μL; Promega). Firefly and
Renilla luciferase activities in the cell lysates were mea-
sured in dual wavelength in a MicroLumatPlus LB96 lu-
minometer (Berthold) after sequential addition of the
LAR II reagent (40 μL), stop buffer (40 μL), and the
Glo reagent to the lysates (8 μL). The Dual-luciferase
reporter assay kit was purchased from Promega. To com-
pare the results, the mean values of relative luciferase activ-
ity were used. The levels of the different constructs wereMol Cancer Res; 8(2) February 2010 247
. © 2010 American Association for Cancer Research. 
Sohn et al.
248
Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 compared with the level of the pGL3-hTERT and to the
level of the pGL3-basic vector.
Quantification of hTERTmRNA
For the reverse transcription-PCR analysis, 2 × 105
HEK293 cells per well were precultured at 37°C in a hu-
mid atmosphere containing 5% CO2 for 24 h in 24-well
plates containing culture medium (0.5 mL; supplemented
with 10% fetal bovine serum without antibiotics). Trans-
fection was done with the LipofectAMINE 2000 reagent
(Invitrogen) according to the instructions of the manufac-Mol Cancer Res; 8(2) February 2010
on January 6, 2014mcr.aacrjournals.org Downloaded from turer. The cells were harvested for reverse transcription-
PCR analysis and telomere repeat amplification protocol
(TRAP) assay. RNA was extracted with the RNeasy mini
kit (Qiagen) according to the instructions of the manufac-
turer. The reverse transcription reactions were done with
100 ng of total RNA using Quatitect reverse transcription
kit (Qiagen). To analyze mRNA quantities, 1 μL of the
cDNAs generated from the reverse transcription reactions
were amplified using hTERT-specific primers [5′-GCG
GAA GAC AGT GGT GAA CT-3′ (forward) and 5′-
AGC TGG AGT AGT CGC TCT GC-3′ (reverse)].FIGURE 1. Artificial ZFPs that bind a 12-bp recognition sequence within the core promoter of the hTERT gene and the electrophoretic mobility shift assay.
A, schematic representation of the sequences of the hTERT core promoter and the ZFP-TF. The sequences of the four zinc finger domain-binding sites
are shown in boldface. The probe DNA sequences for electrophoretic mobility shift assay are underlined. B, expression vector constructs for ZFP-KRAB
artificial transcriptional repressors. Zinc finger domains were designed and assembled on a pcDNA3 vector that included the hemagglutinin-epitope,
nuclear localization signal, and the KRAB repression domain. The resulting zinc finger expression vectors pF-197RK, pF-153RK, pF-122RK, pF-105RK,
pF-97RK, and pF-5RK consist of four zinc finger domains. The amino acid sequence of the each ZFP DNA binding domain is described in Materials and
Methods. C, pGEX-4T2 protein expression vector construct for ZFPs. Fusion proteins were purified using glutathione-S-transferase affinity columns
and then digested with thrombin. D, to determine dissociation constants, 2-fold serial dilutions of the ZFPs were incubated with labeled probe DNA
(100 pmol/L) at room temperature for 1 h, and then the reaction mixtures were subjected to gel electrophoresis. Autoradiography signals were quantitated
by NIH ImageJ software. Arrows, positions of the ZFP DNA–bound shift bands. Dotted line arrows, positions of the free-probe bands. Negative control
(NC) means that ZFP-TF expression vector which does not target the hTERT core promoter.Molecular Cancer Research
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 The specific hTERT mRNA amounts were normalized to
the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA quantities calculated by specific amplification using
primers [5′-CAA TGA CCC CTT CAT TGA CC-3′ (for-
ward) and 5′-GAT CTC GCT CCT GGA AGA TG-3′
(reverse)]. Amplification of hTERT-specific and GAPDH-
specific cDNAs was monitored and analyzed with Quanti-
Tect SYBR Green PCR kit (Qiagen) and Rotorgene 3000
Real-time Cycler (Corbett Research). Calculations of rela-
tive expression levels were done using the 2−ΔΔCt method
(34), by normalizing to GAPDH expression levels.
Telomerase Activity Assay
Telomerase activity in cell lysates was measured by
TRAP assay (26) using TRAPEZE telomerase detection
kit (Chemicon) according to the instructions of the man-
ufacturer. PCR products were separated by electrophoresis
on 12.5% nondenaturing polyacrylamide gels, which were
stained with SYBR Green (Molecular Probes). TSR8 and
CHAPS lysis buffer (provided in the TRAPEZE kit) were
used as positive and negative controls, respectively. Telo-
merase activity was semiquantified by normalizing the
band intensities of the characteristic 6 bp telomerase-
specific ladder to those of the 36 bp internal standard using
NIH ImageJ software.
Cell Proliferation Assay
Colorimetric cellular proliferation assay was done using
Cell Counting Kit-8 (Dojindo) according to the instruc-
tions of the manufacturer. Absorbance at 450 nm was mea-
sured using VersaMax microplate reader (Molecular
Devices). To compare the results, the mean values of rela-
tive proliferation rates were used. The levels of the different
constructs were compared with the level of the pcDNA3-
null vector and HEK293 cell.
Telomere Length
Telomere restriction fragment length was determined
using the Telo-TAGGG-Telomere Length Kit (Roche),
following the instructions of the manufacturer. Genomic
DNA was isolated from the pellets of cells grown in culture
for 100 d using QIAamp DNA Mini Kit (Qiagen) and
separated on a 0.8% agarose gel in 1× TAE buffer.Results
Target DNA Binding Specificity and Affinity of the
Artificial ZFP-TFs
Using zinc finger domains with sequences from the
human genome, six four-fingered ZFPs targeting 12-bp
sequences (Table 1) could be generated at the −197,
−153, −122, −105, −97, and −5 upstream regions of
the ATG initiation codon in the core promoter of
hTERT (Fig. 1A). When each ZFPs was incubated with
labeled probe containing target sequences, only the pro-
tein-binding probes showed shifted bands, confirming
the specificities of each artificial ZFP (Fig. 1B-D). Disso-www.aacrjournals.org
on January 6, 2014mcr.aacrjournals.org Downloaded from ciation constant (Kd) values of F-197R, F-153R, F-122R,
F-105R, F-97R, and F-5R were 7.5, 8.4, 4.5, 26.3, 14.8,
and 28.7 pmol/L, respectively, indicating much higher
affinity among each value than in the case of the widely
used three-fingered ZFPs the Kd values of which were
0.01 to 10 nmol/L (25).
Our results suggested that the four-fingered artificial
ZFP-TFs, which recognize 12-bp DNA sequences, could
be a novel tool for the regulation of the target gene at
the transcriptional level.
Suppression of Reporter Gene Expression by
Artificial ZFP-TFs
To examine the efficiency of the artificial ZFP transcrip-
tional repressor in regulating genes, we used the firefly
luciferase reporter gene under the hTERT core promoter.
We developed a new reporter plasmid that contains a well-
characterized hTERT core promoter (Fig. 2A). HEK293
cells were cotransfected with pGL3-hTERT (luciferase re-
porter plasmid) containing the appropriate ZFP bindingFIGURE 2. Effect of artificial ZFP-TFs on luciferase production driven by
the hTERT core promoter. A, schematic representation of the reporter
plasmid. Luciferase reporter pGL3-basic is a promoterless and
enhancerless vector. For luciferase activity assay control, the
pGL3-hTERT luciferase reporter vector was generated by the insertion
of the hTERT core promoter, 334 bp upstream of the initiation ATG
codon. For cloning of the hTERT core promoter, hot-start, touchdown,
GC-rich, and nested PCRs were done using HeLa Genomic DNA. B,
reporter vectors and ZFP-TFs expression vectors were cotransfected in
HEK293 cells. After incubation for 48 h, luciferase activity assays were
done. Negative control (NC) was done by ZFP-TF expression vector
which does not target the hTERT core promoter. Graphs indicate the
mean values and SEs of three independent experiments.Mol Cancer Res; 8(2) February 2010 249
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 sites, together with pcDNA3 (expression plasmid) which
expresses ZFPs fused with KRAB transcriptional repression
domain. The high luciferase activity of pGL3-hTERT re-
markably decreased when appropriate ZFPs which could
bind to hTERT core promoter were expressed. F-197RK,
F-153RK, F-122RK, F-105RK, F-97RK, and F-5RK
showed 94.5%, 86.2%, 94.7%, 86.8%, 87.8%, and
79.2% repression, respectively, of the hTERT core promoter
activated transcription of the luciferase gene (Fig. 2B).
These data indicate that all of the ZFP-TFs designed in
this experiment specifically bound within the promoter
and actually repressed the expression of target gene at the
cellular level.
Artificial ZFP-TFs Suppressed Endogenous hTERT
Gene Expression, Reduction of Telomerase Activity,
and Inhibition of Cell Proliferation
To achieve the transcriptional repression of endogenous
hTERT gene expression, six ZFPs with specificities to the
core promoter of hTERT were fused to the nuclear local-
ization signal and the KRAB transcriptional repression
domain (Fig. 1B). HEK293 cells were transfected using
pF-197RK, pF-153RK, pF-122RK, pF-105RK, pF-
97RK, pF-5RK, and pcDNA3-null vector (control), re-
spectively. Transfected cells were maintained in medium
with 500 μg/mL of G-418 antibiotics. Selected cells were
harvested at 2, 4, 8, and 12 days after transfection. En-
dogenous hTERT mRNA quantities measured by real-
time reverse transcription-PCR were reduced as the time
of culture increased (Fig. 3A). 2−ΔΔCt values of the pF-
197RK, pF-153RK, pF-122RK, pF-105RK, pF-97RK,
and pF-5RK were 0.285, 0.205, 0.219, 0.331, 0.243,
and 0.219, respectively, when measured at 12 days pas-
sage, indicating stable repression of endogenous hTERT
gene by artificial ZFPs.
Telomerase activity of HEK293 cells was also reduced by
ZFP-TFs, as evaluated by the TRAP assay (Fig. 3B and C).
Control HEK293 cells with or without pcDNA3-null vec-Mol Cancer Res; 8(2) February 2010
on January 6, 2014mcr.aacrjournals.org Downloaded from tor showed the same high levels of telomerase activity,
whereas pF-197RK, pF-153RK, pF-122RK, pF-105RK,
pF-97RK, and pF-5RK all showed significantly decreased
levels of telomerase activity.
Induction of six ZFP-TFs expression caused a time-de-
pendent decrease of the cell proliferation rate (Fig. 3D).
Relative cell proliferations of the pF-197RK, pF-153RK,
pF-122RK, pF-105RK, pF-97RK, and pF-5RK were
53.3%, 43.4%, 48.1%, 38.6%, 60.3%, and 44.5%, re-
spectively, at 12 days passage.
Stable Repression of Endogenous hTERT
pF-197RK, pF-153RK, pF-122RK, pF-105RK, pF-
97RK, pF-5RK, and pcDNA3-null vector–transfected
HEK293 cells could be cultured for 100 days in medium
containing 100 μg/mL of G-418–selective antibiotics. The
inhibition of hTERTmRNA (Fig. 4A) and telomerase ac-
tivity (Fig. 4B) persisted for up to 100 days in the culture,
indicating stable repression of endogenous hTERT by
ZFP-TFs.
Artificial ZFP-TFs Shorten Telomere Length
Analysis of terminal restriction fragments by Southern
blotting showed that the telomere lengths observed in con-
trol pcDNA3-null vector were 4.8 kb, similar to that of
parental HEK293 cells. In contrast, telomere lengths in
pF-197RK, pF-153RK, pF-122RK, pF-105RK, pF-
97RK, and pF-5RKwere all shortened, with lengths of
3.5, 3.1, 3.9, 3.0, 3.1, and 3.2 kb, respectively, measured
at 100 days after transfection (Fig. 4C). These observations
indicate that stable suppression of hTERT by artificial
ZFP-TFs functionally inhibits telomerase activity and
shortens telomere length in human cancer cells.
Discussion
We have designed four-fingered ZFP-TFs targeting the
hTERT promoter region using zinc finger domains naturallyTable 1. Binding sites and identity of ZFPs used in hTERT repressionZFP Binding positions* F1 F2 F3. © 2010F4 American ATarget DNA sequence (from 5′ to 3′)F-197RK −197R† QSHR2‡ QSSR1 RSHR QSNR3 GAA GGG GCA GGA
F-153RK −153R RDER1 RSHR CSNR1 RDHT CGG GAC GGG GCG
F-122RK −122R RSHR VSTR RSHR RSNR GAG GGG GCT GGG
F-105RK −105R RDHT RSHR VSTR RSHR GGG GCT GGG AGG
F-97RK −97R RSHR RSNR RSHR QSNR3 GAA GGG GAG GGG
F-5RK −5R RSHR DSCR RDER1 RSHR GGG GTG GCC GGG
NC – RSHR RSHR RSHR RSHR GGG GGG GGG GGG*Numbers in the binding position indicate a 3′ end of the binding site relative to the ATG start codon.
†R, reverse strand.
‡Each zinc finger was named using the single abbreviation of the four amino acid residues at positions −1, 2, 3, and 6 in the α-helix
of the zinc finger.Molecular Cancer Research
ssociation for Cancer Research. 
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Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 existing in the human genome. Although the probability
of four-fingered ZFPs recognizing 12 bp DNA sequences
(412 = 2 × 107) is much lower than the whole human ge-
nome (3 × 109), considering the portion of the promoter
region of unique gene in the whole genome, it is believed
that four-fingered ZFPs are very safe and would not affect
other genes. With high affinity and high specificity of
four-fingered ZFPs as well as high efficiency of ZFPs isolated
from human genome (25), the four-fingered ZFPs we have
designed would be very ideal for gene controls.
Our results showed that artificial four-fingered ZFP-
TFs targeting the promoter region of the hTERT couldwww.aacrjournals.org
on January 6, 2014mcr.aacrjournals.org Downloaded from reduce the expression of telomerase at the transcriptional
level with actual telomere shortening, and actual prolifer-
ation of human cancer cells was inhibited, although the
inhibition level was not strong enough to kill cancer cells.
Several other genetic approaches have also been described
to block telomerase expression or biogenesis by ribozyme,
antisense, and small interfering RNA agents whose levels
of telomerase inhibition, including the present results,
were mostly similar but much lower than those of direct
inhibitors such as pharmacologic drugs and chemical
agents (15, 29-31). From the 4th day, hTERT expression
was suppressed by artificial ZFP-TFs, whereas actual cellFIGURE 3. Repression of endogenous hTERT using artificial ZFP-TFs. A, to analyze relative quantitative gene expression at the hTERT mRNA level
using real-time PCR with the 2−ΔΔCt method, results with the reference gene (GAPDH) were compared with those of the target gene (hTERT). After RNA
extraction, reverse transcription was done. The resulting cDNA was subjected to real-time PCR using gene-specific primers (sequences are shown in
Materials and Methods). Gene expression profiles of pF-197RK, pF-153RK, pF-122RK, pF-105RK, pF-97RK, pF-5RK, pcDNA3-null vector, and HEK293
(control) were analyzed by real-time PCR using the 2−ΔΔCt method. Samples were collected at 2, 4, 8, or 12 d after transfection. A HEK293 sample
was selected as the calibrator. For the calibrator, ΔΔCt equals zero and 2
0 equals one, so that the fold change in gene expression in HEK293 equals one,
by definition. For other samples, evaluation of 2−ΔΔCt represents the fold change in gene expression relative to HEK293. B, telomerase activity after
transfection with artificial ZFP-TFs. HEK293 cell lysates incubated for 2 to 12 d were tested for telomerase activity via the TRAP assay. PCR products were
separated by gel electrophoresis, and gels were stained with SYBR Green. Arrows, positions of the 36 bp internal control bands. Negative control (NC)
corresponds to use of CHAPS lysis buffer. C, to determine relative telomerase activities, signal densities of the bands were quantitated by NIH ImageJ
software, and then each unit of total product generated (TPG) was calculated according to the instructions of the manufacturer. Telomerase activity values
represent percentage values of TPG relative to HEK293 cells. D, cell proliferation assay. Each of six ZFP-TFs inhibits the growth of HEK293 cells.Mol Cancer Res; 8(2) February 2010 251
. © 2010 American Association for Cancer Research. 
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Published OnlineFirst February 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0141 proliferation was beginning to be inhibited as late as al-
most the 12th day of culture. This might indicate the
possibility of another direct controlling pathway to inhib-
it cell growth other than telomere shortening–related cel-
lular inhibition.
Many approaches using designed ZFPs with activator
domains were used to activate dormant genes (16, 24).
Recent activation of dormant tumor suppressor gene
showed the inhibition of proliferation and invasion of
tumor cell line (35, 36). We expect that the attach-
ment of an activator domain to our ZFP-TF targeting
the hTERT promoter region could also lead to interest-
ing results, as telomerase activity and telomere lengths
are closely related to cell aging. There are many trials
using gene insertion (37, 38). Telomerase activation us-
ing ZFPs should be unique in that a dormant gene is
activated.Mol Cancer Res; 8(2) February 2010
on January 6, 2014mcr.aacrjournals.org Downloaded from Although there are many trials for inhibition of telomer-
ase (15, 29-31), telomerase gene repression using gene-reg-
ulating proteins such as ZFP-TFs could be advantageous,
as this could suggest the new possibility of protein drugs
regulating gene expression. Each isolated human ZFP
tagged with protein transduction domains (39, 40) could
be directly used for repression or activation of telomerase
activity. Many combinations of ZFP-TFs could even be
possible for maximum efficiency. Further studies are ex-
pected in this field.
Telomerase and telomeres are attractive targets for an-
ticancer therapy. As tumors have relatively short telo-
meres, human cancers can be more susceptible to
cancer drug when telomerase is inhibited. The repression
of telomerase expression by artificial ZFP-TFs presents a
new promising strategy for inhibiting the growth of hu-
man cancer cells.FIGURE 4. Stable repression of endogenous hTERT. Samples were collected at 100 d after transfection. A, quantitative gene expression profiles of six
ZFP-TFs, pcDNA3-null vector, and HEK293 (control) were analyzed by real-time PCR. B, TRAP assay. Relative signal densities of the bands are summarized
(bottom). C, Southern blot assay to measure the telomere length of HEK293 cells, control clones (HEK293 and pcDNA3-null vector), and artificial
ZFP-TF expressing clones (pF-197RK, pF-153RK, pF-122RK, pF-105RK, pF-97RK, and pF-5RK).Molecular Cancer Research
. © 2010 American Association for Cancer Research. 
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